KURA ONCOLOGY, INC. (NASDAQ:KURA) Files An 8-K Other Events
Item 8.01
Kura Oncology, Inc. Exhibit
EX-99.1 2 d849850dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Kura Oncology Receives Fast Track Designation for Tipifarnib in HRAS Mutant HNSCC and Provides Enrollment Guidance for AIM-HN Trial – Fast Track designation highlights potential for tipifarnib to address unmet need for patients with HRAS mutant HNSCC – – Registration-directed AIM-HN trial expected to complete enrollment in first quarter of 2021 – SAN DIEGO,…
To view the full exhibit click here
About KURA ONCOLOGY, INC. (NASDAQ:KURA)
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small molecule product candidates that targets cell-signaling pathways, which drives the progression of certain cancers. It is developing its lead product candidate, tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with tumors that have mutations in or other dysregulation of the mitogen-activated protein kinase (MAPK), signaling pathway, including pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma.
